T-cells are a critical component of the adaptive immune system and are indispensable in protecting humans from pathogenic infections.
A new way to significantly increase the potency of almost any vaccine has been developed by researchers from the International Institute for Nanotechnology at Northwestern University.
The Stem Cell and Bone Marrow Transplant Program at Cedars-Sinai Cancer was recently recognized with two important hallmarks of quality: official accreditation for CAR T-cell therapy, and a third year in a row ranking among the top adult bone marrow transplant programs in the U.S.
Afamitresgene autoleucel (afami-cel; formerly ADP-A2M4), an adoptive T cell receptor (TCR) therapy targeting the MAGE-A4 cancer antigen, achieved clinically significant results for patients with multiple solid tumor types in a Phase I clinical trial led by researchers at The University of Texas MD Anderson Cancer Center.
A new cell-intrinsic mechanism has been unraveled by scientists at the University of Basel. This regulates the correct number of T cells present in the organism and thus guarantees that the immune system functions in a proper manner.
After analyzing data from a public repository, CD4-T, CD8-T cells, and Treg cells, a team of researchers led by bioinformatics Mabel Vidal from the University of Concepcion and working with researchers from MELISA Institute and other academic institutions discovered a distinctive genetic signature among subsets of infiltrating T cells of various types of cancer.
The task of battling cancer cells can fatigue T cells employed in immunotherapy treatments, or they could shut down once they penetrate tumors. Researchers at the Gladstone Institutes and UC San Francisco have strengthened the therapeutic cells’ resistance via a CRISPR-based edit on their genomes.
In CAR T-cell immunotherapy, T cells taken from the patient’s own blood are modified to contain so-called chimeric antigen receptors (CAR), which provide the T cells the ability to target and eradicate tumor cells.
A minimally invasive technique was created and improved by scientists at Terasaki Institute for Biomedical Innovation (TIBI) to develop immunotherapeutic cancer treatments.
Researchers from the National Institute of Allergy and Infectious Diseases (NIAID) Vaccine Research Center (VRC) and their collaborators gave a presentation recently at AIDS 2022, the 24th International AIDS Conference in Montreal.
The potential of CAR T-cell therapy for the treatment of solid tumors was unlocked in a preclinical trial by researchers at St. Jude Children’s Research Hospital who discovered a molecular mechanism. The findings were released in the journal Nature.
The interferon-gamma receptor (IFNgR) signaling pathway has been identified to be crucial for the vulnerability of glioblastoma tumors to death by CAR T-cell immunotherapy, according to researchers at Massachusetts General Hospital (MGH).
A new study performed has offered better knowledge about how genetic factors tend to impact the immune response of the body in type 1 diabetes.
An immunological problem has been addressed by scientists at St. Jude Children’s Research Hospital. Despite being genetically identical, a CD8+ T cell can divide and produce two functionally different daughter cells.
CAR T therapy, or chimeric antigen receptor T-cell therapy, has revolutionized the treatment of some blood cancers, allowing patients with relapsed or refractory disease to live longer and better lives.
A vaccine for hepatitis C has eluded scientists for more than 30 years, for several reasons. For one, the virus that causes the disease comes in many genetic forms, complicating the creation of a widely effective vaccine.
Researchers from North Carolina State University and the University of North Carolina at Chapel Hill have developed an implantable biotechnology that produces and releases CAR-T cells for attacking cancerous tumors.
Researchers at the University of Michigan Rogel Cancer Center found that a cytokine, a category of protein that acts as messengers in the body, and a fatty acid can work together to trigger a type of cell death previously defined by studies with synthetic molecules.
Cutaneous T-cell lymphoma (CTCL) is an incurable, rare cancer of skin-homing T cells that is highly disfiguring and lethal at advanced stages.
Blocking a protein chain reaction makes childhood leukemia cells more sensitive to an existing targeted treatment, a new study shows.
When the immune system fails and assaults the body’s own components, autoimmune disorders develop.